Biobab AiBIO utilizes artificial intelligence and Cryo-EM technology to develop novel pharmaceuticals, focusing on enhancing drug discovery efficiency. The company addresses the challenge of slow and costly drug development processes by streamlining molecular analysis and candidate selection.
Funding
$14.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery processes are often slow, expensive, and inefficient, hindering the rapid development of novel pharmaceuticals. Analyzing molecular structures and selecting promising drug candidates can be particularly challenging and time-consuming.
Solution
Baobab AiBIO leverages artificial intelligence (AI) and Cryo-EM technology to accelerate and enhance drug discovery. The company's integrated platform streamlines molecular analysis, improves candidate selection, and ultimately aims to reduce the time and cost associated with bringing new drugs to market. By combining advanced imaging techniques with AI-driven insights, Baobab AiBIO seeks to identify and develop innovative treatments more effectively.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking to improve the efficiency and effectiveness of their drug discovery efforts.
Features
- AI-driven platform for molecular analysis and drug candidate selection
- Cryo-EM technology for high-resolution structural determination of biomolecules
- Integrated AI/Cryo-EM pipeline for streamlined drug discovery